ProShares UltraShort NASDAQ Biotechnology
1 hedge funds and large institutions have $43K invested in ProShares UltraShort NASDAQ Biotechnology in 2013 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
87% less capital invested
Capital invested by funds: $333K → $43K (-$290K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$50.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$310K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$21.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $43K | +$50.1K | +52 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$310K | -304 | Closed |
|
|
U
3
UBS
Zurich,
Switzerland
| – | -$21.2K | -22 | Closed |
|
BIS Hedge Fund Activity: Q4 2013 in Review
1 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2013, worth a combined $43K — down 87% from $333K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $50.1K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $310K sold.
- 1 institutional investor held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2013, down from 2 in Q3 2013.
- Funds reported $43K of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2013, down 87% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2013 and 2 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2013 was Tower Research Capital (TRC), an estimated $50.1K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2013 was Susquehanna International Group, an estimated $310K sold.
Based on aggregated 13F filings for Q4 2013.